Skip to content

Depreciation at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
Tango Therapeutics logo
Tango TherapeuticsTNGX
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$1.94B+436%
Enterprise value$1.79B+1,855%
P/S60.4×+58.5×

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0.0×
Current ratio+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stoke Therapeutics, Inc.'s depreciation?
Stoke Therapeutics, Inc. (STOK) reported depreciation of $439K in Q1 2026.
How has Stoke Therapeutics, Inc.'s depreciation changed year-over-year?
Stoke Therapeutics, Inc.'s depreciation decreased by 8.0% year-over-year, from $477K to $439K.
What is the long-term trend for Stoke Therapeutics, Inc.'s depreciation?
Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s depreciation has grown at a 16.1% compound annual growth rate (CAGR), from $974K to $1.77M.